BioStock: Strong momentum for Curasight in first half of 2022

2022 has so far been eventful for Danish biotech Curasight. Adding two more indications to its strategy during the spring, the company is now waiting for results from the investigator-initiated phase II study with uTRACE in brain cancer. BioStock contacted CEO Ulrich Krasilnikoff for a comment on the Q2 report released last week.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/09/strong-momentum-for-curasight-in-first-half-of-2022/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se